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 Curcumin has been known to have a variety of biological activities in different diseases, 
including inflammation, cancer, and diabetes. The limited bioavailability of curcumin is due to 
its low solubility and extensive metabolism, rendering curcumin unusable as an oral therapeutic 
agent. The aim of the study is to enhance the solubility and bioavailability of curcumin by 
preparing curcumin-piperine solid dispersion (SD) utilizing the hot-melt extrusion technique. 
Three physical mixtures with different ratios were prepared as following: F1 (5% w/w piperine, 
15% w/w curcumin, 80% w/w Soluplus®), F2 (10% w/w piperine, 30% w/w curcumin, 60% 
w/w Soluplus®), and F3 (15% w/w piperine, 45% w/w curcumin, 40% w/w Soluplus®). The 
extrusion process was conducted using two different extrusion temperatures, 130 °C and 140 °C, 
to study the effect of temperature on physicochemical properties. Differential scanning 
calorimetry (DSC) was used to obtain the thermal characterization of the extrudates with a 
heating rate of 10 °C/min, ranging 20 to 200 °C. Additionally, Fourier transform infrared 
spectroscopy (FTIR) was performed to evaluate the chemical interaction between the 
components. Surface morphologies of the extrudates were analyzed utilizing the scanning 
electron microscope. Drug release studies for the pure compounds and the extrudates were 
performed using the USP apparatus II, and the samples were analyzed using high-performance 
liquid chromatography (HPLC). 
Curcumin-piperine solid dispersion was successfully prepared by the hot-melt extrusion 
technology. DSC results showed the presence of endothermic peaks, one for curcumin at 179 °C, 
and another for piperine at 132 °C. However, these peaks were not observed in the extrudates’ 
 iii 
thermograms, indicating the solubilization of curcumin and piperine within the polymeric carrier 
at an amorphous state. The formation of hydrogen bonds between the components was observed 
in the FTIR spectra. Results from drug release studies showed enhancements in curcumin release 
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1.1. Solubility improvement of poorly soluble drugs: 
The oral bioavailability of a drug relies on several factors including aqueous solubility, 
dissolution rate, drug permeability, first pass metabolism, and pre-systemic metabolism. Drug 
solubility is a key factor to achieve the desired concentration of a drug in the blood circulation 
that is required to produce a pharmacological effect. Moreover, drug solubility is considered a 
major challenge during the drug development process. 
In recent years, several technologies have emerged in the pharmaceutical field to develop new 
drugs with high affinity and selectivity for their targets. Computational modeling, high 
throughput screening, and combinatorial chemistry are examples. However, a drawback of such 
strategies is that the synthesized drug tends to have a low bioavailability (1).  
Interestingly, it has been reported that 50% of the discovered and synthesized drugs are 
classified as class II under the biopharmaceutical classification system (poorly water-soluble 
drugs, Table 1) (2). According to the U.S pharmacophobia, the drug is water-soluble when the 
maximum dose is soluble in 250 ml of aqueous media with pH range of 1 to 7.5 (3). In order to 
overcome the solubility barrier, several techniques have been applied to enhance the drug 
solubility and increasing the bioavailability. These include solid dispersion, salt formation, 





Table 1. The biopharmaceutical classification system (BCS) 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
 
1.2. Solid dispersion: 
Solid dispersion is a strategy to enhance drug solubility, dissolution rate, and 
bioavailability. With the increase in numbers of poorly water-soluble drugs, solid dispersion has 
been vigorously investigated as an approach to overcome the limitations of many drugs. Several 
solid dispersion formulations have been approved and marketed, indicating the effectiveness of 
this approach (Table 2) (5). The concept of solid dispersion is based on the combination of at least 
two different components, a hydrophobic drug and a hydrophilic carrier, in which the 
hydrophobic drug is dispersed in the hydrophilic carrier at a solid-state. 
 
Table 2. Examples of commercially available solid dispersions.  
Brand Name Manufacturer Drug 
Gris-PEG Pedinol Pharmacal Inc. Griseofulvin 
Kaletra Abbott Lopinavir, ritonavir 
Intelence Tibotec Etravirin 
Certican Novartis Everolimus 
Cesamet Valeant Pharmaceuticals Nabilone 
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The classification of solid dispersions mainly depends on the physical state of the 
polymeric carrier (crystalline or amorphous) and the way that the drug is dispersed in the matrix. 
Three different types of solid dispersions can be prepared by utilizing crystalline matrix: eutectic, 
amorphous precipitates in a crystalline matrix, and solid solution. Whereas, glass suspension and 
glass solution can be achieved using an amorphous matrix (Table 3) (6) . 
 
Table 3. Types of solid dispersion. 
Type of solid dispersion Matrix Drug 
Eutectic Crystalline Crystalline 
Amorphous precipitate in crystalline matrix Crystalline Amorphous 
Solid solutions Crystalline Molecularly dispersed 
Glass suspension Amorphous Crystalline 
Glass suspension Amorphous Amorphous 
Glass solution Amorphous Molecularly dispersed 
 
Modifying the physical state and reducing the particle size of the drug are advantages of 
using the solid dispersion approach (5). The solubility and the bioavailability of poorly water-
soluble drugs will also be improved (5). According to the Noyes-Whitney equation (equation 1), 
the reduction in the particle size can improve drug wettability and reduce particle agglomeration 
by increasing the surface area in contact with the dissolution media. Moreover, changing the 
physical state of the drug to a high free energy state (an amorphous state) can enhance drug 






= 𝐴𝐷(𝐶𝑆 − 𝐶𝑡)/ℎ                                               (Equation 1) 
 
 Where: 
dM/dt = the dissolution rate 
A = the specific surface area 
D = the diffusion coefficient 
Cs = the saturation solubility  
Ct = drug concentration at time t 
h = the diffusion layer thickness 
 
1.3. Hot-melt extrusion: 
Different techniques have been applied to prepare solid dispersion formulations, 
including hot-melt extrusion, spray drying, melt fusion, and the supercritical fluid technique. 
Hot-melt extrusion (HME) is an efficient and successful technique for manufacturing 
pharmaceutical products. In the 1980s, HME was first introduced in the pharmaceutical industry, 
and before that, it was used in food and plastics industries. 
HME is the solution for several pharmaceutical challenges, including poor solubility, insufficient 
stability, unpalatable taste, and manufacturing of films. As any pharmaceutical technique, HME 






Table 4. Advantages and disadvantages of HME 
Advantages Disadvantages 
Continuous processing 
Few processing steps 
Solvent free 
Low cost 
Easy to scale-up 
High throughput 
Temperature 
Not suitable to process heat-sensitive drugs 
 
In terms of applications, HME technique has been used to develop different dosage forms 
for different drug delivery systems. These include sustained released tablets(9), pellets (10), 
granules (11), transdermal dosage form (12), and implants (13). Furthermore, additional benefits can 
be provided by HME over the traditional techniques, since it’s a solvent-free and continuous 
process, and it has a low cost and a small footprint. 
HME technique relies on three major steps, melting, mixing, and shaping. The mixture of 
a polymer and an active pharmaceutical ingredient (API) passes through three zones. First, the 
mixture is fed through the feeder and transferred to the melting zone by the barrels. In the 
melting zone the mixture begins to soften, then moves to the mixing zone where the drug is 
dispersed within the polymer. The shaping zone has the function of reducing the pulsation flow 
and maintaining a uniform delivery rate throughout the die (Figure 1) (2). 
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Figure 1(2). A schematic for the hot-melt extrusion process. 
 
1.4. Active pharmaceutical ingredients: 
1.4.1. Curcumin: 
Curcumin is one of the major ingredients derived from turmeric (Curcuma Longa Linn). 
For many years, curcumin was the preferred choice in home remedies to treat several diseases, 
especially in Indian traditional medicine (14). In the last two decades, scientists have been 
investigating the efficiency of curcumin against many diseases. Moreover, curcumin has shown 
significant pharmacological impacts as an anti-cancer(15), anti-inflammatory, and anti-microbial 
drug (16). However, it is rapidly metabolized by glucuronidation, which is the major metabolic 
pathway that transforms curcumin into less active metabolites, dehydrocurcumin, 
tetrahydrocucumin, and hexahydrocurcumin(19). Additionally, it is classified under class IV of the 
biopharmaceutical classification system (low solubility and low permeability) (18). These 
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disadvantages decrease the bioavailability of curcumin, and limiting its efficacy as a promising 
drug (18). 
The chemical structure of curcumin contains three essential functional groups. Two 
phenolic ring systems containing methoxy functional groups and a seven-carbon linker that 
contain a diketone moiety, as shown in figure 2. The diketone moiety undergoes keto-enol 
tautomerism, and depending on the environment, either one can be the major tautomer (17).   
  
 
Figure 2. The chemical structure of curcumin. 
 
1.4.2. Piperine: 
Piperine is the main component of black pepper (Piper nigrum Linn). It has been widely 
used as a spicy flavor in food. Recently, a great deal of studies has shown that piperine has a 
therapeutic potential as an anti-depressant, anti-inflammatory, antioxidant, and anti-cancer agent 
(20, 21). Another important property of piperine that has been deeply investigated by scientists is 
the ability of piperine to be used as a metabolic inhibitor (22). It has been reported that piperine 
can increase the bioavailability of other drugs by inhibiting several metabolic enzymes, such as 
cytochrome P-450 (CYP3A4, CYP2E1, CYP1B2, CYP1B1), UDP- glucanosyltransferases, and 




The objective of this study was to increase the bioavailability of curcumin by enhancing 
its solubility and decreasing its rapid metabolism. To achieve that, HME was used to prepare a 
solid dispersion of curcumin and piperine utilizing the hydrophilic polymer (Soluplus®). Piperine 
was incorporated as a metabolic inhibitor to protect curcumin from being extensively 
metabolized. Important parameters such as the effect of extrusion temperature, loading capacity 




















Curcumin and piperine were purchased from Fisher Scientific (Fair Lawn, NJ, USA) and 
Sigma-Aldrich (Milwaukee, WI, USA), respectively. Soluplus® was obtain as a gift from BASF-
SE (Ludwigshafen, Germany). All other chemicals and solvents were of analytical grade and 
were purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
 
2.2.Methods  
2.2.1. Hot-melt extrusion 
Three physical mixtures were prepared with different ratio of the components (curcumin, 
piperine, and Soluplus®, Table 5). The physical mixtures were blended using V-shell blender for 
10 minutes (Patrtreson-Kelley twin shell dry blender). The resulting physical mixtures were 
extruded using the co-rotating twin-screw extruder (11 mm twin screw extruder, Thermo Fisher 
Scientific). The selected screw configuration consisted of four conveying zones and three mixing 
zones, as seen in figure 3. Two different extrusion temperatures were applied for each 








Table 5. Composition of the three formulations. 
Formulation Curcumin Piperine Soluplus® 
F1 15% 5% 80% 
F2 30% 10% 60% 























F1 130 1 75 40 % 
F1 140 1 75 25 % 
F2 130 1 75 30 % 
F2 140 1 75 22 % 
F3 130 1 75 16 % 
F3 140 1 75 15 % 
 
 
2.2.2. Differential scanning calorimetry (DSC) 
The physical state of the components before and after the extrusion process were 
evaluated using differential scanning calorimetry (DSC) (TA instruments DSC 25 Discovery 
series) with a heating rate of 10 °C /min ranging from 20 to 200 °C. The weights of the samples 
were between 3 to 6 mg, and the weighed samples were placed in aluminum pans. Trios software 
was used to analyze the thermograms of the samples. 
 
2.2.3. Scanning electron microscopy (SEM) 
The surface morphologies of all extrudates were characterized using the scanning 
electron microscope (SEM, JEOL, JSM-7200). The samples were mounted on carbon pad placed 
on aluminum stub and sputter-coated with gold. The process was conducted with an accelerating 
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voltage of 5 kV. 
 
2.2.4. Fourier transform infrared spectroscopy (FTIR) 
Fourier transform infrared spectroscopy (Agilent Cary 630 with a DTGS detector) was 
performed to study the interaction between the components. Weighed samples (2–4 mg) were 
analyzed using a scanning range from 1000 to 4000 cm-1 with a resolution of 1 cm-1. 
 
2.2.5. Drug content 
  Known amounts of compounds from each formulation F1 (130 °C and 140 °C), F2 (130 
°C and 140 °C), and F3 (130 °C and 140 °C) were dissolved in acetonitrile, then the solutions 
were placed on the vortex stirrer (Scientific industries vortex genie-120V) for one minute for 
good mixing. Standard calibration curves were performed with r2 between 0.99 to 1. High 
performance liquid chromatography (HPLC) consisting of a Waters 2695 separation Module and 
Waters 2489 UV/Visible detector (Waters Technologies Corporation, Milford, USA) was used to 
analyze the samples. The mobile phase was a mixture of 0.1% orthophosphoric acid in water and 
acetonitrile (50:50 v/v). The chromatography was done using the Phenomenex C8 column (5 
microns, 150 * 4.6 mm) and a flow rate of 0.8 mL/min with a 10 µL injection volume, and a 
column temperature of 35 °C with a wavelength of 262 nm. 
 
2.2.6. In-vitro drug release studies 
In-vitro drug release studies were performed to evaluate the release profiles for the 
formulations F1 (130 °C and 140 °C), F2 (130 °C and 140 °C), and F3 (130 °C and 140 °C) 
along with the pure compounds (curcumin and piperine). The study was conducted using USP 
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apparatus II, and a dissolution medium of 900 mL 0.1 N HCL (pH 1.2) with 0.1% sodium lauryl 
sulfate (SLS) and a paddle speed of 100 rpm. The temperature of the medium was maintained at 
37 °C during the study. A sample volume of 2 ml was taken at predetermined time points 15, 30, 
45, 60, 90, 120, 150, and 180 min, and 2 mL of fresh medium was added each time to maintain 
the volume at 900 mL. The samples were centrifuged for 10 min at 13,000 rpm, then the 
supernatants were analyzed using the HPLC (25). All dissolution experiments were conducted in 
triplicates. Similarity factors were calculated to compare the drug release profiles of the different 
formulations. Moreover, the drug release kinetic was evaluated using an open source software 
KinetDS.  
  
2.2.7. Stability studies 
A 3-month stability study was performed under the conditions of 25 °C and 60% 
humidity. Tests were conducted at months 0 and 3. A portion from each extrudate was packed in 
a glass vial and stored in the stability chamber. The study was conducted to evaluate the integrity 










3. RESULTS AND DISCUSSION 
 
3.1. Hot-melt extrusion 
According to the standard HME procedure, the starting extrusion temperature preferred to 
be above the polymer glass transition temperature by 40 degrees and lower than the drug 
degradation temperature. Since the glass transition (Tg) for Soluplus® was 75 °C, and the 
melting points for curcumin and piperine were 180 °C and 130 °C, respectively, the first starting 
temperature was chosen to be 115 °C. Unfortunately, at both 115 °C and 120 °C extrusion 
temperatures, the physical mixture was stuck inside the instrument. To adjust the extrusion 
temperature, 130 °C was selected to be the extrusion temperature. On the other hand, 140 °C was 
also used to evaluate the effect of the extrusion temperature on the physicochemical properties of 
the formulations. Other extrusion parameters such as the feeding rate and the screw speed were 
kept the same during the extrusion process for all formulations (Table 6).
The extrudates’ appearances shown in figure 4, F1 and F2 had light red, and brown red 
color, respectively. Whereas, the appearance of F3 was different, having a brown black color. 
This indicates that only a small percent of the drug was dissolved in the matrix for F3 due to high 




                
                                                                                 
                                    
Figure 4. Physical appearance of the extrudates (A) F1 (5%Pip, 15%Cur, 80%Solu with 
temperature 130 °C), (B) F1 (5%Pip, 15%Cur, 80%Solu with temperature 140 °C), (C) F2 
(10%Pip, 30%Cur, 60%Solu with temperature 130 °C), (D) F2 (10%Pip, 30%Cur, 60%Solu with 
temperature 140 °C), (E) F3 (15%Pip, 45%Cur, 40%Solu with temperature 130 °C), (F) F3 
(15%Pip, 45%Cur, 40%Solu with temperature 140 °C). 
 
3.2. Differential scanning calorimetry (DSC) 
Thermal analysis was performed to evaluate different parameters, including the melting 
points of curcumin and piperine, and the glass transition temperature for Soluplus®. Moreover, 
DSC was conducted to investigate the physical state of the drugs, physical mixtures, and 
extrudates. Thermograms of curcumin and piperine revealed endothermic peaks at temperature 
132 °C and 180 °C, respectively. The endothermic peaks indicate that curcumin and piperine are 
A B C D 
E F 
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existing in crystal states. Moreover, the glass transition temperature for Soluplus® was at 75 °C 
(Figure 5). 
It can be observed from figure 6 that the physical mixtures’ thermograms for 
formulations F2 and F3 have two endothermic peaks at temperatures 110 °C and 160 °C. Both 
peaks are lower than the melting points of pure piperine and curcumin (132 °C and 180 °C, 
respectively), implying that fractions of piperine and curcumin still exist in crystalline form. The 
intensities of the peaks are larger for F3 than F2, due to the increase in the drug loading. 
Additionally, the physical mixture of formulation F1 showed only one peak at 170 °C for 
curcumin. Thermal analysis of Formulations F1 (130 °C and 140 °C), F2 (130 °C and 140 °C), 
and F3 (130 °C and 140 °C) showed only one peak at around 70 °C, corresponding to the 
polymer glass transition temperature. The absence of the endothermic peaks in the thermogram 





Figure 5. Thermogram of pure curcumin, pure piperine, and Soluplus®. 
 
Figure 6. Thermogram of the physical mixtures of the three formulations, F1 (5%Pip, 15%Cur, 
80%Solu), F2 (10%Pip, 30%Cur, 60%Solu), and F3 (15%Pip, 45%Cur, 40%Solu). 
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Figure 7. Thermogram of the three formulations, F1 (130 °C and 140 °C), F2 (130 °C and 140 
°C), and F3 (130 °C and 140 °C). 
 
3.3. Scanning electron microscopy 
The surface morphology of F1 with drug loading (5% piperine, 15% curcumin, 80% 
Soluplus®), and F2 (10% piperine, 30% curcumin, 60% Soluplus®) showed smooth surfaces with 
absent of crystals. These images suggested the solubilization of the drugs within the polymeric 
carrier at an amorphous form (Figures 8 and 9). Moreover, crystal appearance was evident in F3, 
due to high drug loading (15% piperine, 45% curcumin, 40% Soluplus®) that exceeded the 
polymeric carrier capacity, as seen in figure 10. SEM images for F3 were inconsistent with DSC 
thermal analysis, which showed no appearance of drug crystalline peaks in the extrudates. This 
could be due to the fact that the polymer has a transition glass temperature of 75 °C, which is 
lower than the drugs’ melting points. Consequently, the polymer will soften and solubilize the 
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Figure 8. SEM images for all formulations. A- F1 with extrusion temperature 130 °C, and B- F1 
with extrusion temperature 140 °C. C- F2 with extrusion temperature 130 °C, and D- F2 with 
extrusion temperature 140 °C. E- F3 with extrusion temperature 130 °C, and F- F3 with 
extrusion temperature 140 °C. 
 
3.4. Fourier transforms infrared spectroscopy 
Hydrogen bonding interactions between the components could facilitate the solubilization 
and enhance the stability for the formulations. FTIR was performed to determine the presence of 
hydrogen bonds between the components. The FTIR spectra of both curcumin and Soluplus® 
revealed sharp peaks at 1626 for carbonyl group, which were broadened in all formulation 
implying the presence of hydrogen bonds. Additionally, the disappearance of the hydroxyl peak 
at 3507 in curcumin and the methylenedioxy peak at 2940 in peiperine support the formation of 









Figure 9. FTIR analysis of the three formulations, A- F1 with extrusion temperatures 130 °C, 
and 140 °C. B- FT-IR analysis for formulation F2 with extrusion temperatures 130 °C, and 140 
°C. C- FT-IR analysis for formulation F3 with extrusion temperatures 130 °C, and 140 °C. 
 
3.5. Drug content 
Three weighed samples (25–40 mg) from each formulation F1 (130 °C and 140 °C), F2 
(130 °C and 140 °C), and F3 (130 °C and 140 °C) were dissolved in 20 mL of acetonitrile. The 
samples were analyzed using HPLC at a wavelength of 262 nm. The results showed that all 
formulations have drug contents with the range of 80% to 100% for both curcumin and piperine 





Table 7. The percent drug content of curcumin.   
Formulation Drug content % 
F1 with extrusion temperature 130 °C 100 
F1 with extrusion temperature 140 °C 98 
F2 with extrusion temperature 130 °C 85 
F2 with extrusion temperature 140 °C 100 
F3 with extrusion temperature 130 °C 92 
F3 with extrusion temperature 140 °C 99 
  
Table 8. The percent drug content of piperine. 
Formulation Drug content % 
F1 with extrusion temperature 130 °C 96 
F1 with extrusion temperature 140 °C 100 
F2 with extrusion temperature 130 °C 80 
F2 with extrusion temperature 140 °C 98 
F3 with extrusion temperature 130 °C 94 
F3 with extrusion temperature 140 °C 98 
 
3.6. In-vitro drug release studies 
The release study for pure curcumin showed a negligible amount of drug release, 13%. 
The deficiency in curcumin release profile is due to its low aqueous solubility.  
The release profiles of curcumin in F1, F2, and F3, with both extrusion temperatures (130 °C and 
140 °C), have significantly increased for up to 9-folds compared to the pure drug. When 
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analyzing the release profiles of curcumin, F1 with the extrusion temperatures (130 °C and 140 
°C) had a percent release of 93%, which was the highest (Figure 12). Moreover, the percent 
release in F2 with both extrusion temperature (130 °C and 140 °C) were 86% and 77%, 
respectively (Figure 13). The highest drug loading (45%) F3 had the lowest release profile 
compared to F1 and F2, 65% for both extrusion temperatures (130 °C and 140 °C), as seen in 
figure 14. The increase of drug loading within the formulations affected the drug release, 
implying that a portion of the drug is still in the crystal form or did not completely dissolve 
within the carrier.   
Piperine had different release profiles, where F1 with both extrusion temperatures (130 
°C and 140 °C) showed percent releases of 100% and 94%, respectively, compared to pure 
piperine (75%). Whereas, F2 and F3 with both extrusion temperatures (130 °C and 140 °C) have 
not showed a significant improvement in the release profiles.     
Both curcumin and piperine had improved drug release profiles for all HME 
formulations. This is a consequence of particle size reduction and the resulting increase in 
surface area. Moreover, low energy is required to break the crystal lattice to release the drug 





Figure 10. The release profiles for F1 formulations, with extrusion temperatures of A- 130 °C, 























F1-130 °C Drug Release Study






















F1-140 °C Drug Release Study






Figure 11. The release profiles for F2 formulations, with extrusion temperatures of A- 130 °C, 






















F2-130 °C Drug Release Study






















F2-140 °C Drug Release Study






Figure 12. The release profiles for F3 formulations, with extrusion temperatures of A- 130 °C, 






















F3-130 °C Drug Release Study






















F3-140 °C Drug Release Study




Similarity factors were calculated to compare the drug release profiles between the 
formulations prepared with different extrusion temperatures (equation 2) (26). As shown in tables 
9, the similarities in the dissolution profiles had f2 values higher than 50, and closer to 100. 
Based on this result, the difference in temperature showed no impact on the release of the drugs. 
 
F2= 50.log{[1+(1/n) ∑ (Rt-Tt)2}]-05                                     (Equation 2) 
 
 








f2 similarity f2 similarity 
F1 with extrusion temperature 130 °C 
& 
F1 with extrusion temperature 140 °C 
67 Yes 84.5 Yes 
F2 with extrusion temperature 130 °C 
& 
F2 with extrusion temperature 140 °C 
69 Yes 77.5 Yes 
F3 with extrusion temperature 130 °C 
& 
F3 with extrusion temperature 140 °C 
75 Yes 94 Yes 
 
 
 Curcumin release kinetics were determined by regression coefficient (R2) for each 
formulation utilizing several release models, as seen in tables 10-12. The results indicate that 





Table 10. F1 dissolution kinetic calculations                          
Model F1- 130 °C F1- 140 °C 
Zero order 0.6227 0.6291 
First order 0.2298 0.2305 
Korsmeyer-Peppas 0.9961 0.9962 
Weibull 0.9988 0.9987 
Hickson-Crowell 0.3773 0.3826 
Higuchi -2.9481 -2.8870 
Hill equation 0.9998 0.9999 
 
 
Table 11. F2 dissolution kinetic calculations 
Model F2- 130 °C F2- 140 °C 
Zero order 0.6477 0.6546 
First order 0.2302 0.2302 
Korsmeyer-Peppas 0.9961 0.9961 
Weibull 0.9983 0.9978 
Hickson-Crowell 0.3831 0.3837 
Higuchi -2.9202 -2.9018 





Table 12. F3 dissolution kinetic calculations                       
Model F3- 130 °C F3- 140 °C 
Zero order 0.7675 0.8325 
First order 0.2368 0.2413 
Korsmeyer-Peppas 0.9971 0.9976 
Weibull 0.9982 0.9987 
Hickson-Crowell 0.4446 0.4868 
Higuchi -2.3905 -2.1058 
Hill equation 0.9993 0.9996 
 
 
3.7. Stability study 
Three months of stability study was conducted 25 °C, and 60% humidity. A portion from 
each extrudate was packed in a glass vial and stored in the stability chamber. Tests were 
applied at months 0, and 3. The results from the release studies, drug content, and thermal 
analysis (DSC) showed no difference between the initial formulations and third month. It can 
deduce that’s all formulations were maintained stable physically and chemically during the 






4. CONCLUSION  
Curcumin and piperine formulation were successfully developed utilizing hot 
melt extrusion technique. Furthermore, the enhancement in curcumin dissolution and 
release from the dosage form was achieved up to 9-folds compared to the pure drugs. It 
can be observed from the stability study that’s Soluplus® showed a significant impact as a 
recrystallization inhibitor by maintaining the integrity of the formulations for three 
months. Moreover, there was no impact of the extrusion temperatures (130 °C, 140 °C) 
on the physicochemical properties of the formulations. In vivo study will be conducted to 
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